The recent proliferation of initial public offerings (IPOs) by health care and biotechnology companies is sparking interest among leadership in similar organisations and causing them to wonder whether offering stock to the public to fuel future growth.
This path to expansion and business opportunities has been quite popular lately.
According to data compiled by S&P Global Market Intelligence, 112 global health care and life science (HLS) companies went public globally in the second quarter, more than doubling the number of IPOs in the same quarter in the previous year. The total valuation of these offerings was $28.8 billion — more than half of the combined offering sizes of IPOs in the entirety of 2020 — with the lion’s share of the group consisting of IPOs of health care services and biotechnology companies. Furthermore, the average offering value per IPO increased significantly over the past six years, from $1.44 billion in the second quarter of 2016 to $15.64 billion in the second quarter of 2021.
Medical Consumables M&A Market
June 5, 2025
The medical consumables sector is a vital component of healthcare, underpinning diagnostics, treatment, and infection prevention. With a global market projected to grow from $422 billion in 2025 to $571 billion by 2035, at a CAGR of 3.2%, the sector is poised for steady expansion.
Social Care M&A Market
April 25, 2025
The social care sector is a cornerstone of society, contributing £50 billion annually to the UK economy. It plays a vital role in supporting the well-being and diverse needs of our population. However, it now stands at a critical juncture.
GLOBAL CONSUMER HEALTH M&A MARKET
February 27, 2025
The Consumer Health market, currently valued at over $357 billion globally, is projected to almost double by 2034. Through 2025 and onwards, the Consumer Health market is poised for steady growth. The currently fragmented sector offers potential for roll-up opportunities, driven by widespread demand for an integrated offering.
CONTRACT DEVELOPMENT AND MANUFACTURING ORGANISATIONS M&A MARKET
December 2, 2024
The global Contract Development and Manufacturing Organisations (CDMOs) market, which helps Pharmaceutical and MedTech companies in efficiently developing, manufacturing, and bringing products to market, is valued at $230 billion in 2024, and is anticipated to grow at a CAGR of 8.5% to reach $358 billion by 2029.
